FIELD: medicine.
SUBSTANCE: present invention relates to a liposome formulation for use in a method of treating or preventing tuberculosis, as well as to a suspension containing a dissolved liposomal formulation. Liposome formulation comprises fragments from a Mycobacterium tuberculosis-complex strain, liposome forming agent, 2-6% (w/v) sucrose. Liposomal formulation is characterized by a z- average size of the particles which is 110 nm or less.
EFFECT: invention makes it possible to obtain a formulation with high bioavailability and efficacy.
23 cl, 13 dwg, 6 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MTB-C VACCINE AGAINST ASTHMA | 2012 |
|
RU2602771C2 |
| PREVENTIVE ANTI-TUBERCULOSIS VACCINE | 2007 |
|
RU2526910C2 |
| IMMUNOTHERAPEUTIC AGENT FOR PRIMARY PREVENTION OF TUBERCULOSIS | 2009 |
|
RU2544125C2 |
| IMMUNOTERAPEUTIC AGENT SUITABLE FOR COMBINED TUBERCULOSIS TREATMENT COUPLED WITH OTHER MEDICAL PRODUCTS | 2004 |
|
RU2341287C2 |
| HYBRIDISATION OF HETEROOLIGOMER MYCOBACTERIAL ANTIGENS | 2015 |
|
RU2695462C2 |
| IMMUNOGENIC COMPOSITION (VERSIONS) BASED ON RECOMBINANT INTRACELLULAR PATHOGEN | 2003 |
|
RU2337707C2 |
| POLYANTIGENIC VACCINE FOR PREVENTING AND ADJUNCTIVE TREATMENT OF TUBERCULOSIS | 2019 |
|
RU2724896C1 |
| FUSION PROTEIN, DNA, GENETIC CONSTRUCT, RECOMBINANT CELL, FUSION PROTEIN-BASED VACCINE FOR TUBERCULOSIS PREVENTION AND TREATMENT (VERSIONS) | 2015 |
|
RU2615440C2 |
| NEW EFFECTIVE THERAPEUTIC TARGET FOR TREATING TUBERCULOSIS | 2008 |
|
RU2474621C2 |
| COMPOSITIONS AND METHODS FOR TREATING ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION | 2013 |
|
RU2659149C2 |
